Johnson & Johnson To Present Data On Its FDA-Approved TECNIS PureSee Intraocular Lens At 2026 American Society Of Cataract And Refractive Surgery

Johnson & Johnson (NYSE: JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 10-13 in Washington, DC. TECNIS PureSee IOL is J&J's next-generation Extended Depth of Focus (EDOF) IOL, which demonstrates excellent clinical outcomes and provides significantly improved range of vision* and reduced visual symptoms compared to a monofocal IOL.1^